DUBLIN, Sept. 16, 2020 /PRNewswire/ -- Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced new data from the landmark WRAP-IT study, showing the TYRX™ Absorbable ...
) has received CE (Conformité Européenne) Mark for the TYRX(TM) Absorbable Antibacterial Envelope. This innovative mesh envelope covers an implantable cardiac device to help stabilize the device after ...
Worldwide, an estimated 1.5 million patients receive a cardiovascular implantable electronic device (CIED) such as a pacemaker or implanted defibrillator each year. However, in approximately 1% to 4% ...
One innovative device increasingly championed by cardiologists as a demonstrated deterrent against CIED infection is the TYRX™ Absorbable Antibacterial Envelope. The surgical mesh Envelope holds CIEDs ...
Earlier this month, Medtronic announced FDA clearance of the TYRX Neuro Absorbable Antibacterial Envelope to be used with implantable neurostimulators (INS). The product, a mesh envelope into which ...
Recently Medtronic plc’s MDT TYRX Absorbable Antibacterial Driveline Wrap gained Breakthrough Device Designation. This designation ensures that patients will gain timely access to this product, which ...
DENVER--(BUSINESS WIRE)--Use of TYRX, Inc.’s AIGISRx ® Antibacterial Envelope significantly reduced device infection rates in patients at high risk for device infection who received cardiovascular ...
DUBLIN, Sept. 22, 2020 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, has received Breakthrough Device Designation status from the U.S. Food and Drug Administration ...
> Medtronic ($MDT) has started what it expects to be a 7,000-patient trial for the Tyrx Absorbable Antibacterial Envelope to reduce major infections in surgical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback